Source comparison
TB-500 Long Term Studies: Dosing Protocols Comparison
Equine tendon injury (2023) 6 weeks, 7.5mg 2×/week 18 months Fiber alignment via ultrasound, cross-sectional area 19% better alignment vs controls at month 18 Gains persist but attenuate. Early controlled loading critical for maintenance Rodent myocardial infa
This comparison does not assign a generated winner or score.
- Equine tendon injury (2023)
- 6 weeks, 7.5mg 2×/week
- 18 months
- Fiber alignment via ultrasound, cross-sectional area
- 19% better alignment vs controls at month 18
- Gains persist but attenuate. Early controlled loading critical for maintenance
- Rodent myocardial infarction (2022)
- 24 weeks continuous
- 24 weeks
- Ejection fraction, capillary density, scar tissue
- 18% higher EF, 34% greater capillary density at week 24
- Cardiac tissue shows strongest durability due to constant mechanical demand
- Human tendinopathy case series (2025)
- 16–24 weeks variable
- 24 months
- Pain scores, functional assessments
- 3.8-point pain reduction maintained at month 12
- Subjective endpoints only. Lacks imaging or control group for validation
- Rodent muscle injury (2020)
- 8 weeks
- Muscle CSA, fiber type, strength
- No difference vs controls at week 24
- Accelerated recovery doesn't translate to long-term hypertrophy without continued training
- The comparison reveals a pattern: TB-500 durability correlates with tissue metabolic demand and mechanical loading post-protocol. Not just initial response during active dosing.